董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 尹卫东 | 男 | Chairman, President, Chief Executive Officer | 59 | 未披露 | 635.95 | 2023-05-01 |
| Shan Fu | 男 | Independent Director | 56 | 未披露 | 未持股 | 2023-05-01 |
| 西蒙·安德森 | 男 | Independent Director | 62 | 未披露 | 未持股 | 2023-05-01 |
| Yuk Lam Lo | 男 | Independent Director | 73 | 未披露 | 未持股 | 2023-05-01 |
| 李坎南 | 男 | Independent Director | 55 | 未披露 | 未持股 | 2023-05-01 |
| Meng Mei | 男 | Independent Director | 68 | 未披露 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 尹卫东 | 男 | Chairman, President, Chief Executive Officer | 59 | 未披露 | 635.95 | 2023-05-01 |
| 高强 | 男 | Chief Operating Officer, Vice President | 46 | 未披露 | 未持股 | 2023-05-01 |
| 李静 | 女 | Vice President, Quality and Production | 49 | 未披露 | 未持股 | 2023-05-01 |
| Guang Yang | 女 | Chief Business Officer | 43 | 未披露 | 未持股 | 2023-05-01 |
| 王楠 | 女 | Chief Financial Officer, Vice President | 56 | 未披露 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- 尹卫东
-
尹卫东自2003年9月起担任Sinovac Biotech Ltd.董事长、总裁、首席执行官和秘书。他之前在河北省唐山市中国疾病预防控制中心担任传染病医生。尹先生致力于肝炎研究已有20多年，在Helive的发展中发挥了重要作用。此外，尹先生还被中国科技部任命为许多关键政府研发项目的首席研究员，如Inactivated Hepatitis A Vaccine R&D、Inactivated SARS Vaccine R&D和New Human Influenza Vaccine H5N1 R&D。他还是Zhongguancun Listed Companies Association主席。他在National University of Singapore获得了工商管理硕士学位。
Weidong Yin,has served as Sinovac Biotech Ltd. chairman, president, chief executive officer and secretary since September 2003. He previously worked as a medical doctor in infectious disease at the China Center for Disease Control and Prevention, Tangshan City, Hebei province. Mr. Yin has been dedicated to hepatitis research for over 20 years and was instrumental in the development of Healive. In addition, Mr. Yin has been appointed as the principal investigator by the Chinese Ministry of Science and Technology for many key governmental R&D programs such as Inactivated Hepatitis A Vaccine R&D, Inactivated SARS Vaccine R&D and New Human Influenza Vaccine (H5N1) R&D. He is also the president of Zhongguancun Listed Companies Association. He obtained his MBA from the National University of Singapore. - 尹卫东自2003年9月起担任Sinovac Biotech Ltd.董事长、总裁、首席执行官和秘书。他之前在河北省唐山市中国疾病预防控制中心担任传染病医生。尹先生致力于肝炎研究已有20多年，在Helive的发展中发挥了重要作用。此外，尹先生还被中国科技部任命为许多关键政府研发项目的首席研究员，如Inactivated Hepatitis A Vaccine R&D、Inactivated SARS Vaccine R&D和New Human Influenza Vaccine H5N1 R&D。他还是Zhongguancun Listed Companies Association主席。他在National University of Singapore获得了工商管理硕士学位。
- Weidong Yin,has served as Sinovac Biotech Ltd. chairman, president, chief executive officer and secretary since September 2003. He previously worked as a medical doctor in infectious disease at the China Center for Disease Control and Prevention, Tangshan City, Hebei province. Mr. Yin has been dedicated to hepatitis research for over 20 years and was instrumental in the development of Healive. In addition, Mr. Yin has been appointed as the principal investigator by the Chinese Ministry of Science and Technology for many key governmental R&D programs such as Inactivated Hepatitis A Vaccine R&D, Inactivated SARS Vaccine R&D and New Human Influenza Vaccine (H5N1) R&D. He is also the president of Zhongguancun Listed Companies Association. He obtained his MBA from the National University of Singapore.
- Shan Fu
-
Shan Fu自业务合并完成以来，一直担任公司董事。 自2013年10月起，傅先生一直担任Vivo Capital LLC的执行合伙人，联席首席执行官和大中华区首席执行官，该公司主要投资于生物技术和医疗保健领域。 诺华生物技术有限公司董事 纳斯达克（Nasdaq）：SVA自2018年7月起担任TOT BIOPHARM International Co.Ltd.的董事。 自2016年1月起（HKSE：01875）担任InnoCare Pharma Ltd.的董事。 自2018年2月（HKSE：09969）开始。傅先生在2008年6月至2013年10月期间担任黑石（上海）股权投资管理有限公司北京分公司的高级董事总经理。 傅先生分别于1991年和1988年在北京大学获得历史学硕士学位和历史学学士学位。
Shan Fu,has served as Genetron Holdings Limited director since June 2021. Prior to joining Genetron Holdings Limited Company, Mr. Fu served as joint chief executive officer and the greater China chief executive officer of Vivo Capital LLC since October 2013, prior to which he served as the chief representative of China at Blackstone Group from June 2008 to October 2013. Mr. Fu served as a non-executive director of Sinovac Biotech Ltd., (a company listed on the Nasdaq, symbol: SVA) since July 2018, of TOT BIOPHARM International Company Limited (a company listed on the Stock Exchange, stock code: 1875) since November 2019, and of InnoCare Pharma Limited (a company listed on the Stock Exchange, stock code: 9969) since March 2020. Mr. Fu obatined his bachelor's degree in history from Peking University in Beijing, the PRC in July 1988 and his master's degree in history from Peking University in July 1991. - Shan Fu自业务合并完成以来，一直担任公司董事。 自2013年10月起，傅先生一直担任Vivo Capital LLC的执行合伙人，联席首席执行官和大中华区首席执行官，该公司主要投资于生物技术和医疗保健领域。 诺华生物技术有限公司董事 纳斯达克（Nasdaq）：SVA自2018年7月起担任TOT BIOPHARM International Co.Ltd.的董事。 自2016年1月起（HKSE：01875）担任InnoCare Pharma Ltd.的董事。 自2018年2月（HKSE：09969）开始。傅先生在2008年6月至2013年10月期间担任黑石（上海）股权投资管理有限公司北京分公司的高级董事总经理。 傅先生分别于1991年和1988年在北京大学获得历史学硕士学位和历史学学士学位。
- Shan Fu,has served as Genetron Holdings Limited director since June 2021. Prior to joining Genetron Holdings Limited Company, Mr. Fu served as joint chief executive officer and the greater China chief executive officer of Vivo Capital LLC since October 2013, prior to which he served as the chief representative of China at Blackstone Group from June 2008 to October 2013. Mr. Fu served as a non-executive director of Sinovac Biotech Ltd., (a company listed on the Nasdaq, symbol: SVA) since July 2018, of TOT BIOPHARM International Company Limited (a company listed on the Stock Exchange, stock code: 1875) since November 2019, and of InnoCare Pharma Limited (a company listed on the Stock Exchange, stock code: 9969) since March 2020. Mr. Fu obatined his bachelor's degree in history from Peking University in Beijing, the PRC in July 1988 and his master's degree in history from Peking University in July 1991.
- 西蒙·安德森
-
西蒙·安德森，自2004年7月起担任Sinovac Biotech Ltd.的独立董事。他是Sinovac Biotech Ltd.审计委员会主席，也是Sinovac Biotech Ltd.薪酬委员会和公司治理和提名委员会的成员。他为在北美证券交易所上市的公司和私营企业提供监管合规、交易所上市和金融运营方面的咨询服务。他是Chartered Professional Accountants of British Columbia的成员，于1986年获得特许会计师资格。他担任IBC Advanced Alloys Corp.的董事，IBC Advanced Alloys Corp.在其美国工厂生产和加工合金。
Simon Anderson,has served as an independent director of Sinovac Biotech Ltd. since July 2004. He is the chairman of Sinovac Biotech Ltd. audit committee and a member of Sinovac Biotech Ltd. compensation committee and corporate governance and nominating committee. Mr. Anderson advises companies listed on North American stock exchanges and private businesses in the areas of regulatory compliance, exchange listings and financial operations. He is a member of the Chartered Professional Accountants of British Columbia, having qualified as a Chartered Accountant in 1986. Mr. Anderson serves as a director of IBC Advanced Alloys Corp., which manufactures and processes alloys at its U.S. plants. - 西蒙·安德森，自2004年7月起担任Sinovac Biotech Ltd.的独立董事。他是Sinovac Biotech Ltd.审计委员会主席，也是Sinovac Biotech Ltd.薪酬委员会和公司治理和提名委员会的成员。他为在北美证券交易所上市的公司和私营企业提供监管合规、交易所上市和金融运营方面的咨询服务。他是Chartered Professional Accountants of British Columbia的成员，于1986年获得特许会计师资格。他担任IBC Advanced Alloys Corp.的董事，IBC Advanced Alloys Corp.在其美国工厂生产和加工合金。
- Simon Anderson,has served as an independent director of Sinovac Biotech Ltd. since July 2004. He is the chairman of Sinovac Biotech Ltd. audit committee and a member of Sinovac Biotech Ltd. compensation committee and corporate governance and nominating committee. Mr. Anderson advises companies listed on North American stock exchanges and private businesses in the areas of regulatory compliance, exchange listings and financial operations. He is a member of the Chartered Professional Accountants of British Columbia, having qualified as a Chartered Accountant in 1986. Mr. Anderson serves as a director of IBC Advanced Alloys Corp., which manufactures and processes alloys at its U.S. plants.
- Yuk Lam Lo
-
Yuk Lam Lo，自2006年3月起担任本公司独立董事。他担任审计，薪酬和公司治理及提名委员会成员。他积极参与香港特区政府多个委员会。他被任命为香港应用研发基金有限公司，香港工商及科技发展局生物技术委员会主席的董事，以及创新及科技基金，香港特区生物科技项目评审委员会主席。目前，他担任香港特别行政区咨询委员会食物及卫生局食品安全委员，香港CMA和CMA的创新科技委员会主席的中国厂商联合会董事。他担任香港生物组织Hononary创会会长。在教育方面，他被选为科技香港大学荣誉院士。他是香港中国大学的兼职教授；亚洲管理学院的执行副总裁；职业训练局顾问委员会的成员和中国几所大学的名誉教授。在中国，他是长春经济局和深圳市科技局咨询委员会委员的一位顾问。目前，他是中国该中心疾病控制与预防的顾问。在工商部门，他担任劳氏联合有限公司的董事长，三泰生态渔业有限公司副主席，Aplus的场外生集团有限公司副主席，Questmark资本管理私人有限公司的高级顾问和Questmark亚洲有限公司高级总监。他为东南国际集团有限公司的尚华医药（NYSE：SHP）的独立董事（0726.HK）。
Yuk Lam Lo,has served as an independent director of Sinovac Biotech Ltd. since March 2006. Mr. Lo is the chairman of Sinovac Biotech Ltd. corporate governance and nominating committee and a member of Sinovac Biotech Ltd. audit committee and compensation committee. Currently Mr. Lo is serving as the Founding President of HK Bio-Med Innotech Association. He is also the Honorary Founding Chairman of Hong Kong Biotechnology Organization. In the educational area, Mr. Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China. Mr. Lo was heavily involved in several committees of the HKSAR Government. He had been served as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. In mainland China, Mr. Lo is a member of Chinese People's Political Consultative Conference in Jilin Province. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Mr. Lo has received many awards, such as the "Pericles International Prize" in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Mr. Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades. In the business sector, Mr. Lo is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited. As at the date of this annual report, Mr. Lo holds directorships in the following listed companies: He is an Independent Non-executive Director of Luye Pharma Group Limited (2186.HK) and an Independent Non-executive Director of Zhaoke Ophthalmology Limited (06622.HK). - Yuk Lam Lo，自2006年3月起担任本公司独立董事。他担任审计，薪酬和公司治理及提名委员会成员。他积极参与香港特区政府多个委员会。他被任命为香港应用研发基金有限公司，香港工商及科技发展局生物技术委员会主席的董事，以及创新及科技基金，香港特区生物科技项目评审委员会主席。目前，他担任香港特别行政区咨询委员会食物及卫生局食品安全委员，香港CMA和CMA的创新科技委员会主席的中国厂商联合会董事。他担任香港生物组织Hononary创会会长。在教育方面，他被选为科技香港大学荣誉院士。他是香港中国大学的兼职教授；亚洲管理学院的执行副总裁；职业训练局顾问委员会的成员和中国几所大学的名誉教授。在中国，他是长春经济局和深圳市科技局咨询委员会委员的一位顾问。目前，他是中国该中心疾病控制与预防的顾问。在工商部门，他担任劳氏联合有限公司的董事长，三泰生态渔业有限公司副主席，Aplus的场外生集团有限公司副主席，Questmark资本管理私人有限公司的高级顾问和Questmark亚洲有限公司高级总监。他为东南国际集团有限公司的尚华医药（NYSE：SHP）的独立董事（0726.HK）。
- Yuk Lam Lo,has served as an independent director of Sinovac Biotech Ltd. since March 2006. Mr. Lo is the chairman of Sinovac Biotech Ltd. corporate governance and nominating committee and a member of Sinovac Biotech Ltd. audit committee and compensation committee. Currently Mr. Lo is serving as the Founding President of HK Bio-Med Innotech Association. He is also the Honorary Founding Chairman of Hong Kong Biotechnology Organization. In the educational area, Mr. Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China. Mr. Lo was heavily involved in several committees of the HKSAR Government. He had been served as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. In mainland China, Mr. Lo is a member of Chinese People's Political Consultative Conference in Jilin Province. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Mr. Lo has received many awards, such as the "Pericles International Prize" in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Mr. Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades. In the business sector, Mr. Lo is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited. As at the date of this annual report, Mr. Lo holds directorships in the following listed companies: He is an Independent Non-executive Director of Luye Pharma Group Limited (2186.HK) and an Independent Non-executive Director of Zhaoke Ophthalmology Limited (06622.HK).
- 李坎南
-
李坎南，是Sinovac的独立董事。他自2011年5月起担任Sinovac Biotech Ltd.董事会成员。2012年7月，董事会任命他为Sinovac Biotech Ltd.薪酬委员会和公司治理和提名委员会成员。他在中国拥有超过20年的私募股权投资、企业融资和业务发展经验。他是SAIF Partners的合伙人。他毕业于Amherst College。
Kenneth Lee,is an independent director of Sinovac. He has served on Sinovac Biotech Ltd. board of directors since May 2011. In July 2012, the board appointed him as a member of Sinovac Biotech Ltd. compensation committee and corporate governance and nominating committee. He has more than 20 years of experience across private equity investments, corporate finance, and business development in China. Mr. Lee was a partner at SAIF Partners. Mr. Lee graduated from Amherst College. - 李坎南，是Sinovac的独立董事。他自2011年5月起担任Sinovac Biotech Ltd.董事会成员。2012年7月，董事会任命他为Sinovac Biotech Ltd.薪酬委员会和公司治理和提名委员会成员。他在中国拥有超过20年的私募股权投资、企业融资和业务发展经验。他是SAIF Partners的合伙人。他毕业于Amherst College。
- Kenneth Lee,is an independent director of Sinovac. He has served on Sinovac Biotech Ltd. board of directors since May 2011. In July 2012, the board appointed him as a member of Sinovac Biotech Ltd. compensation committee and corporate governance and nominating committee. He has more than 20 years of experience across private equity investments, corporate finance, and business development in China. Mr. Lee was a partner at SAIF Partners. Mr. Lee graduated from Amherst College.
- Meng Mei
-
Meng Mei，自2012年3月起担任本公司独立董事。他担任薪酬委员会主席，以及审核及企业管治及提名委员会成员。他于1994年创立清华科技园，由清华大学创立的以培育高成长企业科学园区。他一直是清华科技园自成立以来发展中心主任。他也是清华科技园有限公司董事长，这是一家从事开发，建设和清华科技园的管理，并为设在清华科技园的企业提供服务的公司。清华科技园也参与了中国的风险投资。他担任中国国家科学技术奖评审专家小组。他为清华大学教授和企业家制定了关于创业和新企业的形成课程。他拥有来自清华大学自动化学士学位。
Meng Mei,has served as an independent director of Sinovac Biotech Ltd. since March 2012. Mr. Mei is the chairman of Sinovac Biotech Ltd. compensation committee, and member of Sinovac Biotech Ltd. audit committee and corporate governance and nominating committee. Mr. Mei founded TusPark, a science park established by Tsinghua University in 1994, to incubate high growth companies. He has been the director of TusPark's development center since its inception. Mr. Mei is also the Chairman of TusHoldings Co., Ltd., which is engaged in the development, construction, and management of TusPark and is providing services to enterprises based in TusPark. TusHoldings Co., Ltd. is also involved in venture capital investments in China. Mr. Mei sits on the judging expert panel of China's National Science & Technology Award. He has developed courses on entrepreneurship and new venture formation as a Tsinghua University professor and an entrepreneur. Mr. Mei holds a bachelor's degree in automation from Tsinghua University, PRC. - Meng Mei，自2012年3月起担任本公司独立董事。他担任薪酬委员会主席，以及审核及企业管治及提名委员会成员。他于1994年创立清华科技园，由清华大学创立的以培育高成长企业科学园区。他一直是清华科技园自成立以来发展中心主任。他也是清华科技园有限公司董事长，这是一家从事开发，建设和清华科技园的管理，并为设在清华科技园的企业提供服务的公司。清华科技园也参与了中国的风险投资。他担任中国国家科学技术奖评审专家小组。他为清华大学教授和企业家制定了关于创业和新企业的形成课程。他拥有来自清华大学自动化学士学位。
- Meng Mei,has served as an independent director of Sinovac Biotech Ltd. since March 2012. Mr. Mei is the chairman of Sinovac Biotech Ltd. compensation committee, and member of Sinovac Biotech Ltd. audit committee and corporate governance and nominating committee. Mr. Mei founded TusPark, a science park established by Tsinghua University in 1994, to incubate high growth companies. He has been the director of TusPark's development center since its inception. Mr. Mei is also the Chairman of TusHoldings Co., Ltd., which is engaged in the development, construction, and management of TusPark and is providing services to enterprises based in TusPark. TusHoldings Co., Ltd. is also involved in venture capital investments in China. Mr. Mei sits on the judging expert panel of China's National Science & Technology Award. He has developed courses on entrepreneurship and new venture formation as a Tsinghua University professor and an entrepreneur. Mr. Mei holds a bachelor's degree in automation from Tsinghua University, PRC.
高管简历
中英对照 | 中文 | 英文- 尹卫东
尹卫东自2003年9月起担任Sinovac Biotech Ltd.董事长、总裁、首席执行官和秘书。他之前在河北省唐山市中国疾病预防控制中心担任传染病医生。尹先生致力于肝炎研究已有20多年，在Helive的发展中发挥了重要作用。此外，尹先生还被中国科技部任命为许多关键政府研发项目的首席研究员，如Inactivated Hepatitis A Vaccine R&D、Inactivated SARS Vaccine R&D和New Human Influenza Vaccine H5N1 R&D。他还是Zhongguancun Listed Companies Association主席。他在National University of Singapore获得了工商管理硕士学位。
Weidong Yin,has served as Sinovac Biotech Ltd. chairman, president, chief executive officer and secretary since September 2003. He previously worked as a medical doctor in infectious disease at the China Center for Disease Control and Prevention, Tangshan City, Hebei province. Mr. Yin has been dedicated to hepatitis research for over 20 years and was instrumental in the development of Healive. In addition, Mr. Yin has been appointed as the principal investigator by the Chinese Ministry of Science and Technology for many key governmental R&D programs such as Inactivated Hepatitis A Vaccine R&D, Inactivated SARS Vaccine R&D and New Human Influenza Vaccine (H5N1) R&D. He is also the president of Zhongguancun Listed Companies Association. He obtained his MBA from the National University of Singapore.- 尹卫东自2003年9月起担任Sinovac Biotech Ltd.董事长、总裁、首席执行官和秘书。他之前在河北省唐山市中国疾病预防控制中心担任传染病医生。尹先生致力于肝炎研究已有20多年，在Helive的发展中发挥了重要作用。此外，尹先生还被中国科技部任命为许多关键政府研发项目的首席研究员，如Inactivated Hepatitis A Vaccine R&D、Inactivated SARS Vaccine R&D和New Human Influenza Vaccine H5N1 R&D。他还是Zhongguancun Listed Companies Association主席。他在National University of Singapore获得了工商管理硕士学位。
- Weidong Yin,has served as Sinovac Biotech Ltd. chairman, president, chief executive officer and secretary since September 2003. He previously worked as a medical doctor in infectious disease at the China Center for Disease Control and Prevention, Tangshan City, Hebei province. Mr. Yin has been dedicated to hepatitis research for over 20 years and was instrumental in the development of Healive. In addition, Mr. Yin has been appointed as the principal investigator by the Chinese Ministry of Science and Technology for many key governmental R&D programs such as Inactivated Hepatitis A Vaccine R&D, Inactivated SARS Vaccine R&D and New Human Influenza Vaccine (H5N1) R&D. He is also the president of Zhongguancun Listed Companies Association. He obtained his MBA from the National University of Singapore.
- 高强
高强，自2020年4月起担任Sinovac Biotech Ltd.首席运营官。他于2002年加入Sinovac Beijing，在过去的几年中担任Sinovac Beijing的质量控制经理、质量保证经理、研发经理和研发总监，自2010年以来担任Sinovac LS的总经理，自2016年4月以来担任Sinovac Biotech Ltd.的副总裁。他参与了多个疫苗品种的开发，包括流感疫苗、SARS疫苗、H5N1流感（禽流感）灭活疫苗、EV71疫苗、COVID-19疫苗、正在进行的sIPV疫苗和已申报的23价肺炎疫苗。在他的领导下，SINOVAC BIOTECH LTD成功通过了世界卫生组织的评估，并被选中有资格从荷兰进口脊髓灰质炎灭活疫苗技术，参与全球根除脊髓灰质炎项目。该项目使中国成为仅有的六个有资格获得技术转让的发展中国家之一。他现任北京市病毒学会会员，中国科学院微生物研究所工程硕士导师，北京市科学技术委员会课题评审专家。他持有中华人民共和国农业大学微生物学硕士学位和学士学位。
Qiang Gao,has served as Sinovac Biotech Ltd. chief operating officer since April 2020. Mr. Gao joined Sinovac Beijing in 2002 and has served as quality control manager, quality assurance manager, R&D manager and R&D director at Sinovac Beijing in the past years, the general manager of Sinovac LS since 2010, and Sinovac Biotech Ltd. vice president since April 2016. Mr. Gao has participated in the development of several vaccine varieties, including influenza vaccine, SARS vaccine, inactivated H5N1 influenza (avian flu) vaccine, EV71 vaccine, COVID-19 vaccine, ongoing sIPV vaccine and declared 23-valent pneumonia vaccine. Under his leadership, SINOVAC BIOTECH LTD successfully passed the WHO assessment and were selected to be eligible to import inactivated polio vaccine technology from the Netherlands and participate in the global polio eradication project. This project makes China become one of only six developing countries eligible for the technology transfer. Mr. Gao is currently a member of the Beijing Virus Society, Master of Engineering Supervisor of Institute of Microbiology (Chinese Academy of Sciences), and a subject review expert of the Beijing Municipal Science and Technology Commission. Mr. Gao received a master's degree and a bachelor's degree in microbiology from the University of Agriculture, PRC.- 高强，自2020年4月起担任Sinovac Biotech Ltd.首席运营官。他于2002年加入Sinovac Beijing，在过去的几年中担任Sinovac Beijing的质量控制经理、质量保证经理、研发经理和研发总监，自2010年以来担任Sinovac LS的总经理，自2016年4月以来担任Sinovac Biotech Ltd.的副总裁。他参与了多个疫苗品种的开发，包括流感疫苗、SARS疫苗、H5N1流感（禽流感）灭活疫苗、EV71疫苗、COVID-19疫苗、正在进行的sIPV疫苗和已申报的23价肺炎疫苗。在他的领导下，SINOVAC BIOTECH LTD成功通过了世界卫生组织的评估，并被选中有资格从荷兰进口脊髓灰质炎灭活疫苗技术，参与全球根除脊髓灰质炎项目。该项目使中国成为仅有的六个有资格获得技术转让的发展中国家之一。他现任北京市病毒学会会员，中国科学院微生物研究所工程硕士导师，北京市科学技术委员会课题评审专家。他持有中华人民共和国农业大学微生物学硕士学位和学士学位。
- Qiang Gao,has served as Sinovac Biotech Ltd. chief operating officer since April 2020. Mr. Gao joined Sinovac Beijing in 2002 and has served as quality control manager, quality assurance manager, R&D manager and R&D director at Sinovac Beijing in the past years, the general manager of Sinovac LS since 2010, and Sinovac Biotech Ltd. vice president since April 2016. Mr. Gao has participated in the development of several vaccine varieties, including influenza vaccine, SARS vaccine, inactivated H5N1 influenza (avian flu) vaccine, EV71 vaccine, COVID-19 vaccine, ongoing sIPV vaccine and declared 23-valent pneumonia vaccine. Under his leadership, SINOVAC BIOTECH LTD successfully passed the WHO assessment and were selected to be eligible to import inactivated polio vaccine technology from the Netherlands and participate in the global polio eradication project. This project makes China become one of only six developing countries eligible for the technology transfer. Mr. Gao is currently a member of the Beijing Virus Society, Master of Engineering Supervisor of Institute of Microbiology (Chinese Academy of Sciences), and a subject review expert of the Beijing Municipal Science and Technology Commission. Mr. Gao received a master's degree and a bachelor's degree in microbiology from the University of Agriculture, PRC.
- 李静
李静，自2016年4月起担任Sinovac Biotech Ltd.副总裁。李女士于2015年3月被任命为Sinovac Beijing的质量人员。自2003年加入Sinovac Beijing以来，她在生产和质量职能部门担任过不同的职位，包括质量保证副经理、甲型肝炎疫苗生产部门经理和Sinovac Beijing疫苗生产总监。李女士先后组织完成了EV71疫苗的生产和现场检验，23价肺炎球菌多糖疫苗的商业化生产和应用。作为项目负责人，她组织并领导了甲型肝炎疫苗通过WHO预认证评估，对甲型肝炎疫苗的出口销售起到了很大的推动作用。李女士获得中华人民共和国农业大学生理学硕士学位。
Jing Li,has served as Sinovac Biotech Ltd. vice president since April 2016. Ms. Li was named as quality person of Sinovac Beijing in March 2015. Since she joined Sinovac Beijing in 2003, she has worked in different roles in production and quality function, including quality assurance vice manager, department manager of hepatitis A vaccine production and director of vaccine production at Sinovac Beijing. Ms. Li has successively organized and completed the production and site inspection of EV71 vaccine, the commercial production and application of 23-valent pneumococcal polysaccharide vaccine. As the project leader, she organized and led the effort to pass WHO pre-certification assessment of hepatitis A vaccine, which significantly promoted the export sales of hepatitis A vaccine. Ms. Li received a master's degree in physiology from the University of Agriculture, PRC.- 李静，自2016年4月起担任Sinovac Biotech Ltd.副总裁。李女士于2015年3月被任命为Sinovac Beijing的质量人员。自2003年加入Sinovac Beijing以来，她在生产和质量职能部门担任过不同的职位，包括质量保证副经理、甲型肝炎疫苗生产部门经理和Sinovac Beijing疫苗生产总监。李女士先后组织完成了EV71疫苗的生产和现场检验，23价肺炎球菌多糖疫苗的商业化生产和应用。作为项目负责人，她组织并领导了甲型肝炎疫苗通过WHO预认证评估，对甲型肝炎疫苗的出口销售起到了很大的推动作用。李女士获得中华人民共和国农业大学生理学硕士学位。
- Jing Li,has served as Sinovac Biotech Ltd. vice president since April 2016. Ms. Li was named as quality person of Sinovac Beijing in March 2015. Since she joined Sinovac Beijing in 2003, she has worked in different roles in production and quality function, including quality assurance vice manager, department manager of hepatitis A vaccine production and director of vaccine production at Sinovac Beijing. Ms. Li has successively organized and completed the production and site inspection of EV71 vaccine, the commercial production and application of 23-valent pneumococcal polysaccharide vaccine. As the project leader, she organized and led the effort to pass WHO pre-certification assessment of hepatitis A vaccine, which significantly promoted the export sales of hepatitis A vaccine. Ms. Li received a master's degree in physiology from the University of Agriculture, PRC.
- Guang Yang
Guang Yang自 2021 年 4 月起担任Sinovac Biotech的首席商务官。Yang女士是Sinovac Biotech执行团队的重要成员，负责Sinovac Biotech的全球战略发展。Yang女士于2003年加入北京科兴，在人用疫苗行业拥有近20年的经验。Yang女士目前负责Sinovac Biotech的全球销售和营销管理，专注于全球营销商业战略布局、发展、转型、建设和升级Sinovac Biotech的营销商业网络和体系。她致力于不断提升Sinovac Biotech的营销业务和商业能力，提升和加强Sinovac Biotech的全球品牌影响力。在她的领导下，Sinovac Biotech的产品和服务在 COVID-19 期间已惠及全球 60 多个国家和地区。在国内市场，Yang女士带领团队提升中国疫苗行业的市场定位能力和品牌影响力认知度。Yang女士于2011年以优异的毕业成绩从北京大学和比利时Vlerick Leuven Gent管理学院获得MBA学位。她于2003年获得英国雷丁大学ISMA国际证券投资与银行学荣誉理学硕士学位， 2002年在中国农业大学和科罗拉多大学丹佛国际学校获得经济学（荣誉）学士学位。
Guang Yang,has served as Sinovac Biotech Ltd. Chief Business Officer since April 2021. Ms. Yang is a key member of Sinovac Biotech Ltd. executive team and is responsible for Sinovac Biotech Ltd. worldwide commercial strategic development and operation. Ms. Yang joined Sinovac Beijing in 2003 and has nearly 20 years of experience in human vaccine industry. Ms. Yang is currently in charge of Sinovac Biotech Ltd. global sales and marketing management, focusing on global marketing commercial strategy layout, development, transformation, building and upgrading Sinovac Biotech Ltd. marketing commercial network and system. She is committed to continuously ramping up Sinovac Biotech Ltd. marketing business and commercial capabilities, promoting and strengthening Sinovac Biotech Ltd. global brand influence. Under her leadership, Sinovac Biotech Ltd. products and services have benefited more than 60 countries and regions around the world during the COVID-19 period. In the domestic market, Ms. Yang leads Sinovac Biotech Ltd. team to enhance the market positioning capabilities and brand influence recognition in China's vaccine industry. Ms. Yang obtained her MBA with outstanding graduate results from Peking University & Vlerick Leuven Gent Management School, Belgium in 2011. She received her master's degree of science (Hons) in ISMA International Securities Investment and Banking from the University of Reading, United Kingdom in 2003 and her bachelor's degree in economics (Hons) from China Agricultural University and University of Colorado Denver International School in 2002.- Guang Yang自 2021 年 4 月起担任Sinovac Biotech的首席商务官。Yang女士是Sinovac Biotech执行团队的重要成员，负责Sinovac Biotech的全球战略发展。Yang女士于2003年加入北京科兴，在人用疫苗行业拥有近20年的经验。Yang女士目前负责Sinovac Biotech的全球销售和营销管理，专注于全球营销商业战略布局、发展、转型、建设和升级Sinovac Biotech的营销商业网络和体系。她致力于不断提升Sinovac Biotech的营销业务和商业能力，提升和加强Sinovac Biotech的全球品牌影响力。在她的领导下，Sinovac Biotech的产品和服务在 COVID-19 期间已惠及全球 60 多个国家和地区。在国内市场，Yang女士带领团队提升中国疫苗行业的市场定位能力和品牌影响力认知度。Yang女士于2011年以优异的毕业成绩从北京大学和比利时Vlerick Leuven Gent管理学院获得MBA学位。她于2003年获得英国雷丁大学ISMA国际证券投资与银行学荣誉理学硕士学位， 2002年在中国农业大学和科罗拉多大学丹佛国际学校获得经济学（荣誉）学士学位。
- Guang Yang,has served as Sinovac Biotech Ltd. Chief Business Officer since April 2021. Ms. Yang is a key member of Sinovac Biotech Ltd. executive team and is responsible for Sinovac Biotech Ltd. worldwide commercial strategic development and operation. Ms. Yang joined Sinovac Beijing in 2003 and has nearly 20 years of experience in human vaccine industry. Ms. Yang is currently in charge of Sinovac Biotech Ltd. global sales and marketing management, focusing on global marketing commercial strategy layout, development, transformation, building and upgrading Sinovac Biotech Ltd. marketing commercial network and system. She is committed to continuously ramping up Sinovac Biotech Ltd. marketing business and commercial capabilities, promoting and strengthening Sinovac Biotech Ltd. global brand influence. Under her leadership, Sinovac Biotech Ltd. products and services have benefited more than 60 countries and regions around the world during the COVID-19 period. In the domestic market, Ms. Yang leads Sinovac Biotech Ltd. team to enhance the market positioning capabilities and brand influence recognition in China's vaccine industry. Ms. Yang obtained her MBA with outstanding graduate results from Peking University & Vlerick Leuven Gent Management School, Belgium in 2011. She received her master's degree of science (Hons) in ISMA International Securities Investment and Banking from the University of Reading, United Kingdom in 2003 and her bachelor's degree in economics (Hons) from China Agricultural University and University of Colorado Denver International School in 2002.
- 王楠
王楠，自2013年6月担任本公司的财务总监；自2001年以来起担任本公司北京科兴副总裁。她曾担任北京科兴的副总经理（2001年至2013年），负责业务开发和临床研究。1988至1993年，她在北京大学就读生物学，是中国生命科学学院研究员。从1993年到2001年，她担任北大未名生物工程经理。她在北京大学获得生物学学位；在外经济贸易 大学获得硕士学位。她还于2003年获得了中国北京学院企业家财务管理文凭。
Nan Wang,has served as Sinovac Biotech Ltd. chief financial officer since June 2013. Ms. Wang served as the vice president of Sinovac Beijing from 2001 and the board director since 2009. Ms. Wang oversaw business development, investment and clinical research. Ms. Wang also served as the first general manager of Sinovac Dalian since establishment of this company. During her 20 years of service, Ms. Wang was responsible for Sinovac Biotech Ltd. business development, investment and clinical research. She has been actively promoted Sinovac Biotech Ltd. foreign cooperation, leading domestic and international cooperation negotiations on a number of projects including equity, technology and market, and successfully achieving a number of foreign cooperation. Ms. Wang has led clinical research on many important projects including SARS vaccine (phase I), inactivated H5N1 influenza (avian flu) vaccine, influenza, H1N1 influenza vaccine and EV71 vaccine (Vero Cell), inactivated, and has actively promoted the listing of new products. Ms. Wang received her bachelor's degree in biology from Peking University and her master's degree from University of International Business and Economics, PRC. Ms. Wang also received a diploma in financial management from Beijing College for Entrepreneurs, PRC in 2003.- 王楠，自2013年6月担任本公司的财务总监；自2001年以来起担任本公司北京科兴副总裁。她曾担任北京科兴的副总经理（2001年至2013年），负责业务开发和临床研究。1988至1993年，她在北京大学就读生物学，是中国生命科学学院研究员。从1993年到2001年，她担任北大未名生物工程经理。她在北京大学获得生物学学位；在外经济贸易 大学获得硕士学位。她还于2003年获得了中国北京学院企业家财务管理文凭。
- Nan Wang,has served as Sinovac Biotech Ltd. chief financial officer since June 2013. Ms. Wang served as the vice president of Sinovac Beijing from 2001 and the board director since 2009. Ms. Wang oversaw business development, investment and clinical research. Ms. Wang also served as the first general manager of Sinovac Dalian since establishment of this company. During her 20 years of service, Ms. Wang was responsible for Sinovac Biotech Ltd. business development, investment and clinical research. She has been actively promoted Sinovac Biotech Ltd. foreign cooperation, leading domestic and international cooperation negotiations on a number of projects including equity, technology and market, and successfully achieving a number of foreign cooperation. Ms. Wang has led clinical research on many important projects including SARS vaccine (phase I), inactivated H5N1 influenza (avian flu) vaccine, influenza, H1N1 influenza vaccine and EV71 vaccine (Vero Cell), inactivated, and has actively promoted the listing of new products. Ms. Wang received her bachelor's degree in biology from Peking University and her master's degree from University of International Business and Economics, PRC. Ms. Wang also received a diploma in financial management from Beijing College for Entrepreneurs, PRC in 2003.